Net prices for ovarian cancer drug Lynparza have nearly tripled over the last 6 years.
Archive
Over the last 9 years, GSK gained $2 billion in revenue from price increases on lupus drug Benlysta.
Plus: Digital asset advocates learn to operate in Washington; California just can’t let go of housing regulations; and FREOPP convenes in D.C. in November
Plus: Leveling the playing field for apprenticeships; revisiting investor rules; and the case for more police
Plus: Assessing the Inflation Reduction Act’s effect on energy prices; and an opportunity to promote—and expand—freedom and progress
Plus: Helping students recover from COVID school closures; how cash payments affect those who receive them; and Trump’s misguided approach to crime
Plus: Avik and Gregg's take on Democrats’ prescription drug bill; and a chance to preview—and vote on—our SXSW panel
Plus: More policy victories; reforming America’s approach to nuclear energy; and ways to join our team